Reference health
Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases
27/27 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 27 checked references that resolve
resolves10.1056/NEJMoa040720
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
resolves10.1016/S0140-6736(10)61389-X
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
resolves10.1016/S1470-2045(12)70379-0
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
resolves10.1056/NEJMoa1207506
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
resolves10.1056/NEJMoa1209096
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
resolves10.1200/JCO.2005.04.5252
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
resolves10.1023/A:1006106209527
Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone
resolves10.1158/1078-0432.CCR-06-0931
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
resolves10.1186/1471-2407-10-284
Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases
resolves10.1016/j.canlet.2012.04.001
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
resolves10.1016/j.eururo.2012.10.007
New and Emerging Therapies for Bone Metastases in Genitourinary Cancers
resolves10.1016/j.urology.2004.01.034
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
resolves10.1002/1097-0142(20000615)88:12+<2934::AID-CNCR9>3.0.CO;2-S
Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases
resolves10.1158/1078-0432.CCR-04-2244
First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases
resolves10.1007/s00259-013-2427-6
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
resolves10.1016/S1470-2045(07)70147-X
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
resolves10.1016/j.clgc.2012.07.002
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
resolves10.1200/jco.2013.31.15_suppl.5080
Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes.
resolves10.1200/jco.2013.31.15_suppl.5060
Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial.
resolves10.1016/j.eururo.2012.09.008
A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer
resolves10.1016/j.ejca.2011.12.023
A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
The 6 references without a DOI — listed, not checked
no DOI — not checkedSurvival rates for prostate cancer
no DOI — not checkedSignificant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model
no DOI — not checkedTargeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice
no DOI — not checkedA phase III study of radium-223 dichloride in patients with symptomatic hormone refractory prostate cancer with skeletal metastases (ALSYMPCA)
no DOI — not checkedPain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
no DOI — not checked2022061023594131000_bib30
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1158/1078-0432.ccr-13-1896"><img src="https://citestamp.com/citestamped/10.1158/1078-0432.ccr-13-1896/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1158/1078-0432.ccr-13-1896)